Alain Faivre-Chauvet

Prof. Alain Faivre-Chauvet

CRCI2NA, INSERM, CNRS, CHU Nantes, University of Nantes, F-44000 Nantes, France

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CBClément Bailly
Clément Bailly
PCPierre-François Cléry
Pierre-François Cléry
AFAlain Faivre-Chauvet
Alain Faivre-Chauvet
MBMickael Bourgeois
Mickael Bourgeois
FGFrançois Guérard
François Guérard
CBCaroline Bodet-Milin
Caroline Bodet-Milin
Recent advances in molecular characterization of tumors have allowed identification of new molecular targets on tumor cells or biomarkers. In medical practice, the identification of these biomarkers slowly but surely becomes a prerequisite before any treatment decision, leading to the concept of personalized medicine. Immuno-positron emission tomography (PET) fits perfectly with this approach. Indeed, monoclonal antibodies (mAbs) labelled with radionuclides represent promising probes for theranostic approaches, offering a non-invasive solution to assess in vivo target expression and distribution. Immuno-PET can potentially provide useful information for patient risk stratification, diagnosis, selection of targeted therapies, evaluation of response to therapy, prediction of adverse effects or for titrating doses for radioimmunotherapy. This paper reviews some aspects and recent developments in labelling methods, biological targets, and clinical data of some novel PET radiopharmaceuticals.

1 May 2014 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
MFMathieu Frindel
Mathieu Frindel
NCNathalie Camus
Nathalie Camus
ARAurore Rauscher
Aurore Rauscher
MBMickaël Bourgeois
Mickaël Bourgeois
CACyrille Alliot
Cyrille Alliot
AFAlain Faivre-Chauvet
Alain Faivre-Chauvet

Verified
Journal Article
Open access
PDF file
CBClément Bailly
Clément Bailly
SGSébastien GOUARD
Sébastien GOUARD
FGFrançois Guérard
François Guérard
BCBenjamin Chalopin
Benjamin Chalopin
TCThomas Carlier
Thomas Carlier
MCMichel Chérel
Michel Chérel
Although positron emission tomography (PET) imaging with 18-Fluorodeoxyglucose (18F-FDG) is a promising technique in multiple myeloma (MM), the development of other radiopharmaceuticals seems relevant. CD138 is currently used as a standard marker for the identification of myeloma cells and could be used in phenotype tumor imaging. In this study, we used an anti-CD138 murine antibody (9E7.4) radiolabeled with copper-64 (64Cu) or zirconium-89 (89Zr) and compared them in a syngeneic mouse model to select the optimal tracers for MM PET imaging. Then, 9E7.4 was conjugated to TE2A-benzyl isothiocyanate (TE2A) and desferrioxamine (DFO) chelators for 64Cu and 89Zr labeling, respectively. 64Cu-TE2A-9E7.4 and 89Zr-DFO-9E7.4 antibodies were evaluated by PET imaging and biodistribution studies in C57BL/KaLwRij mice bearing either 5T33-MM subcutaneous tumors or bone lesions and were compared to 18F-FDG-PET imaging. In biodistribution and PET studies, 64Cu-TE2A-9E7.4 and 89Zr-DFO-9E7.4 displayed comparable good tumor uptake of subcutaneous tumors. On the bone lesions, PET imaging with 64Cu-TE2A-9E7.4 and 89Zr-DFO-9E7.4 showed higher uptake than with 18F-FDG-PET. Comparison of both 9E7.4 conjugates revealed higher nonspecific bone uptakes of 89Zr-DFO-9E7.4 than 64Cu-TE2A-9E7.4. Because of free 89Zr’s tropism for bone when using 89Zr-anti-CD138, 64Cu-anti-CD138 antibody had the most optimal tumor-to-nontarget tissue ratios for translation into humans as a specific new imaging radiopharmaceutical agent in MM.

27 November 2015 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
CBCaroline Bodet-Milin
Caroline Bodet-Milin
LFLudovic Ferrer
Ludovic Ferrer
ARAurore Rauscher
Aurore Rauscher
DMDamien Masson
Damien Masson
LRLatifa Rbah-Vidal
Latifa Rbah-Vidal
JBJacques Barbet
Jacques Barbet
Objectives. A phase I pretargeted radioimmunotherapy trial (EudractCT 200800603096) was designed in patients with metastatic lung cancer expressing carcinoembryonic antigen (CEA) to optimize bispecific antibody and labelled peptide doses, as well as the delay between their injections. Methods. Three cohorts of 3 patients received the anti-CEA x anti-histamine-succinyl-glycine (HSG) humanized trivalent bispecific antibody (TF2) and the IMP288 bivalent HSG-peptide. Patients underwent a pre-therapeutic imaging session S1 (44 or 88 nmol/m2 of TF2 followed by 4.4 nmol/m2, 185 MBq, of 111In-labelled IMP288), and, 1-2 weeks later, a therapy session S2 (240 or 480 nmol/m2 of TF2 followed by 24 nmol/m2, 1.1 GBq/m2, 177Lu-labeled IMP288). The pretargeting delay was 24 or 48 hours. The dose schedule was defined based on pre-clinical TF2 pharmacokinetic studies, on our previous clinical data using the previous anti-CEA pretargeting system and on clinical results observed in the first patients injected using the same system in the Netherlands. Results. TF2 pharmacokinetics (PK) was represented by a two-compartment model in which the central compartment volume was linearly dependent on the patient's surface area. PK were remarkably similar, with a clearance of 0.33 +/- 0.03 L/h per m2. 111In- and 177Lu-IMP288 PK were also well represented by a two-compartment model. IMP288 PK were faster (clearance 1.4 to 3.3 l/h). The central compartment volume was proportional to body surface area and IMP288clearance depended on the molar ratio of injected IMP288 to circulating TF2 at the time of IMP288 injection. Modelling of image quantification confirmed the dependence of IMP288 kinetics on circulating TF2, but tumour activity PK were variable. Organ absorbed doses were not significantly different in the 3 cohorts, but the tumour dose was significantly higher with the higher molar doses of TF2 (p < 0.002). S1 imaging predicted absorbed doses calculated in S2. Conclusion. The best dosing parameters corresponded to the shorter pretargeting delay and to the highest TF2 molar doses. S1 imaging session accurately predicted PK as well as absorbed doses of S2, thus potentially allowing for patient selection and dose optimization.

13 January 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
judith delagejudith delage
judith delage
AFAlain Faivre-Chauvet
Alain Faivre-Chauvet
JBJacques Barbet
Jacques Barbet
JFJulie Katrin Fierle
Julie Katrin Fierle
NSNiklaus Schaefer
Niklaus Schaefer
John PriorJohn Prior
John Prior
1C1m-Fc, an anti-tumor endothelial marker 1 (TEM-1) scFv-Fc fusion protein antibody, was previously successfully radiolabeled with 177Lu. TEM-1 specific tumor uptake was observed together with a non-saturation dependent liver uptake that could be related to the number of dodecane tetraacetic acid (DOTA) chelator per 1C1m-Fc. The objective of this study was to verify this hypothesis and to find the best DOTA per 1C1m-Fc ratio for theranostic applications. 1C1m-Fc was conjugated with six concentrations of DOTA. High-pressure liquid chromatography, mass spectrometry, immunoreactivity assessment, and biodistribution studies in mice bearing TEM-1 positive tumors were performed. A multi-compartment pharmacokinetic model was used to fit the data and a global pharmacokinetic model was developed to illustrate the effect of liver capture and immunoreactivity loss. Organ absorbed doses in mice were calculated from biodistribution results. A loss of immunoreactivity was observed with the highest DOTA per 1C1m-Fc ratio. Except for the spleen and bone, an increase of DOTA per 1C1m-Fc ratio resulted in an increase of liver uptake and absorbed dose and a decrease of uptake in tumor and other tissues. Pharmacokinetic models correlated these results. The number of DOTA per antibody played a determining role in tumor targeting. One DOTA per 1C1m-Fc gave the best pharmacokinetic behavior for a future translation of [177Lu]Lu-1C1m-Fc in patients.

1 September 2003
Verified
Journal Article
Closed access
FKFrançoise Kraeber-Bodéré
Françoise Kraeber-Bodéré
AFAlain Faivre-Chauvet
Alain Faivre-Chauvet
LFLudovic Ferrer
Ludovic Ferrer
JVJean-Philippe Vuillez
Jean-Philippe Vuillez
PBPierre-Yves Brard
Pierre-Yves Brard
JBJacques Barbet
Jacques Barbet